Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 5.6% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (NASDAQ: TNDM) is a leading company in insulin delivery and diabetes technology, with a strong presence in the Smart Insulin Management Devices Market. The company has been achieving significant sales and pump shipments, driving its growth in the industry.

Why is Tandem Diabetes Care, Inc. going up?

TNDM stock is up 5.6% on Apr 8, 2026 18:46

• The bullish movement in Tandem Diabetes Care's stock today could be attributed to the company's request for shareholder approval for an increase in shares to its Long-Term Incentive Plan, signaling confidence in its future growth prospects.
• The projected growth in the Smart Insulin Management Devices Market, where Tandem Diabetes Care is a key player, could have also positively impacted investor sentiment and contributed to the stock's rise.
• Despite a reduction in stake by a notable financial institution, the overall market seems optimistic about Tandem Diabetes Care's performance, especially with the upcoming announcement of its first-quarter 2026 financial results, which investors are eagerly anticipating for insights into the company's trajectory.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Tandem Diabetes Care (NASDAQ: TNDM) seeks approval for equity plan, charter changes

Tandem Diabetes Care (NASDAQ: TNDM) is requesting shareholder approval for an increase of 3,260,000 shares to its 2023 Long-Term Incentive Plan, alongside several governance and compensation-related proposals at its upcoming 2026 annual meeting on May 20, 2026. The company also seeks approval for charter amendments concerning director removal rights and officer exculpation, aligning with Delaware law, and the ratification of Ernst & Young LLP as its independent auditor. This comes after a strong 2025 where Tandem Diabetes Care achieved approximately $1.015 billion in worldwide sales and over 126,000 pump shipments.

https://www.stocktitan.net/sec-filings/TNDM/def-14a-tandem-diabetes-care-inc-definitive-proxy-statement-6abf7969693b.html

Smart Insulin Management Devices Market is expected to Hit US$ 27.07 Billion by 2033 | Major Companies - Abbott, Medtronic, Tandem Diabetes Care, Inc., Eli Lilly and Company

The Smart Insulin Management Devices Market reached US$ 12.93 Billion in 2024 and is projected to grow to US$ 27.07 Billion by 2033, exhibiting an 8.6% CAGR during the forecast period. This growth is driven by advanced medical devices integrating insulin delivery with real-time monitoring and data analytics to optimize diabetes care. Key players include Abbott, Medtronic, and Eli Lilly, with significant industry developments in cloud-based AI analytics, bundled reimbursement programs, and closed-loop automated insulin delivery systems.

https://www.openpr.com/news/4458230/smart-insulin-management-devices-market-is-expected-to-hit-us

JPMorgan Chase & Co. Sells 203,183 Shares of Tandem Diabetes Care, Inc. $TNDM

JPMorgan Chase & Co. reduced its stake in Tandem Diabetes Care, Inc. by 36.1% in the third quarter, selling 203,183 shares and now owning 359,071 shares valued at $4.36 million. Despite beating earnings estimates for the quarter, Tandem Diabetes Care remains unprofitable. Analyst sentiment is mixed, with a "Hold" consensus rating, but some firms have upgraded the stock.

https://www.marketbeat.com/instant-alerts/filing-jpmorgan-chase-co-sells-203183-shares-of-tandem-diabetes-care-inc-tndm-2026-04-03/

Tandem Diabetes Care to Announce Q1 2026 Results on May 7

Tandem Diabetes Care, a leading company in insulin delivery and diabetes technology, will release its first quarter 2026 financial and operating results on Thursday, May 7, 2026, after the market closes. The company will also host a conference call and webcast on the same day to discuss these results. This announcement is significant for investors and analysts as it offers key insights into the company's performance and broader industry trends in diabetes management.

https://nationaltoday.com/us/ca/san-diego/news/2026/04/02/tandem-diabetes-care-to-announce-q1-2026-results-on-may-7/

Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026

Tandem Diabetes Care, Inc. (Nasdaq: TNDM) will release its first quarter 2026 financial results after the market closes on Thursday, May 7, 2026. The company will also host a conference call and webcast on the same day at 4:30 pm Eastern Time to discuss these results. Details for accessing the webcast and conference call are provided, including a link for dial-in and information on accessing the archive.

https://www.businesswire.com/news/home/20260402803028/en/Tandem-Diabetes-Care-to-Announce-First-Quarter-2026-Financial-Results-on-May-7-2026

Trending Today

Heating Oil ($HEATOIL) Commodity Forecast: Up 6.1% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Up 5.3% Today

Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 5.5% Today

Mohawk Industries Inc. ($MHK) Stock Forecast: Down 5.3% Today

Paycom Software Inc. ($PAYC) Stock Forecast: Down 6.8% Today

Twilio Inc. Class A ($TWLO) Stock Forecast: Down 5.6% Today

Salesforce.com Inc ($CRM) Stock Forecast: Down 5.2% Today

Sonos Inc. ($SONO) Stock Forecast: Down 6.6% Today

Reddit Inc ($RDDT) Stock Forecast: Down 5.6% Today

Devon Energy Corporation ($DVN) Stock Forecast: Up 5.8% Today

Tandem Diabetes Care, Inc. Price History

10.02.2026 - TNDM Stock was up 6.2%

• Tandem Diabetes Care's positive momentum is due to the launch of the Mobi insulin pump for Android users, expanding accessibility and convenience.
• The company's strategic move to make its Control-IQ+ technology compatible with a broader range of devices aligns with the industry's shift toward smartphone-operated automated insulin delivery systems.
• Favorable analyst attention, such as a price target increase and stock rating upgrade, has bolstered investor confidence in Tandem Diabetes Care's growth potential.
• With the recent completion of a $265 million convertible bond offering, the company's funding and valuation landscape has been reshaped, offering flexibility for future growth but also raising concerns about potential share dilution. It is advisable for investors to monitor the company's utilization of these funds in comparison to its current financial performance.

19.02.2026 - TNDM Stock was up 5.6%

• Despite reporting a Q4 loss, Tandem Diabetes Care exceeded revenue expectations, showcasing strong growth in its top line.
• The exercise of Restricted Stock Units by company executives and insiders selling shares may have initially caused some downward pressure on the stock price.
• A stock upgrade by Piper Sandler and a positive market outlook contributed to the bullish movement, reflecting investor confidence in the company's future prospects.
• The detailed financial overview and competitor comparison provided insights into Tandem Diabetes Care's revenue sources and financial health, potentially reassuring investors and contributing to the positive market sentiment.

06.02.2026 - TNDM Stock was down 5.2%

• The expansion of Tandem's Mobi automated insulin delivery system to Android smartphones, while a positive development for accessibility and user convenience, may have raised concerns about potential competition in the market, leading to a bearish sentiment among investors.
• Despite receiving rating upgrades and achieving over $1 billion in worldwide sales, the market may have reacted negatively to the stock due to profit-taking by investors who were anticipating a bullish run following these positive developments.
• The announcement of further innovations planned for 2026, including a tubeless Mobi pump and an advanced insulin algorithm, could have created uncertainty among investors about the company's ability to maintain its current growth trajectory, contributing to the bearish movement in the stock price.

17.02.2026 - TNDM Stock was up 7.3%

• The positive movement in TNDM stock today could be linked to the company's new product releases, such as insulin pump software and the introduction of Tandem Mobi.
• Despite industry competition and economic challenges, TNDM's solid financial position and emphasis on advanced solutions appear to have appealed to investors.
• The recent net loss in the fourth quarter of 2025 might have been overlooked due to the perceived long-term growth prospects of Tandem Diabetes, contributing to the optimistic sentiment in the market today.

05.02.2026 - TNDM Stock was down 5.4%

• The introduction of Tandem Mobi's compatibility with Android smartphones, potentially broadening its user base, could have prompted concerns about technical issues or integration challenges, leading to uncertainty among investors and selling pressure on the stock.
• Despite receiving favorable analyst upgrades and surpassing $1 billion in worldwide sales, doubts voiced in the healthcare sector may have influenced market sentiment toward Tandem Diabetes Care, contributing to its recent stock decline.
• Anticipation surrounding the company's upcoming innovations in 2026, such as a tubeless Mobi pump and an enhanced insulin algorithm, may have raised expectations while also introducing uncertainty about execution and market reception, resulting in a negative impact on the stock price.
• When considering the expanded market reach, positive ratings, financial achievements, and industry doubts, the collective effect might have created varying investor sentiments, ultimately leading to the recent decline in TNDM stock value.

30.02.2026 - TNDM Stock was down 5.4%

• An amended Schedule 13G/A filing by The Vanguard Group, indicating 0 shares beneficially owned, could have triggered uncertainty among investors.
• An ongoing investigation by the Portnoy Law Firm regarding potential securities fraud linked to malfunctions in Tandem's insulin pumps likely impacted the company's product reliability and financial transparency, resulting in a stock price decline.
• Despite exceeding Q4 earnings estimates, a neutral recommendation from Mizuho and a consensus "Hold" rating from analysts may have contributed to the subdued sentiment surrounding Tandem Diabetes Care, aligning with the bearish market movement.
• The combination of the investigation, neutral recommendations, and the lack of clear bullish sentiments likely intensified selling pressure on TNDM shares, leading to the observable significant bearish movement.

08.03.2026 - TNDM Stock was up 5.6%

• The bullish movement in Tandem Diabetes Care's stock today could be attributed to the company's request for shareholder approval for an increase in shares to its Long-Term Incentive Plan, signaling confidence in its future growth prospects.
• The projected growth in the Smart Insulin Management Devices Market, where Tandem Diabetes Care is a key player, could have also positively impacted investor sentiment and contributed to the stock's rise.
• Despite a reduction in stake by a notable financial institution, the overall market seems optimistic about Tandem Diabetes Care's performance, especially with the upcoming announcement of its first-quarter 2026 financial results, which investors are eagerly anticipating for insights into the company's trajectory.

24.02.2026 - TNDM Stock was down 6.4%

• Despite recent positive developments, Tandem Diabetes Care (TNDM) saw a decrease in stock value.
• Investors may have been discouraged by the company's lack of profitability despite exceeding earnings and revenue projections, prompting some to realize profits.
• While analysts praised TNDM's pay-as-you-go pharmacy model, this alone may not have calmed market worries or profit expectations.
• The decline in stock value could be influenced by broader market trends or factors specific to Tandem Diabetes Care's industry performance.

27.02.2026 - TNDM Stock was down 6.9%

• Tandem Diabetes Care, Inc. experienced a bearish movement due to a significant 19.9% stock price drop following the disclosure of a malfunction in its insulin pumps.
• An investigation regarding potential securities fraud added further uncertainty and negative sentiment towards the company.
• The malfunction in the insulin pumps, which could lead to serious health complications for users, likely raised concerns among investors about the company's product safety and reliability.
• The market reacted strongly to the news, reflecting the importance of transparency and reliability in the healthcare technology sector.

07.03.2026 - TNDM Stock was up 6.2%

• Significant divestment of Tandem Diabetes Care shares by JPMorgan Chase & Co. initially raised investor concerns, but the market sentiment later turned positive.
• Despite Tandem Diabetes Care's ongoing lack of profitability, the stock witnessed a bullish trend leading up to the upcoming Q1 2026 financial results announcement.
• A mix of analyst opinions, resulting in a "Hold" consensus rating, and upgrades from some firms, likely influenced the positive investor sentiment as the company's potential was reassessed.
• Market enthusiasm and confidence in Tandem Diabetes Care's future performance, bolstered by beating earnings estimates for the quarter, drove the stock to a significant bullish movement.

07.03.2026 - TNDM Stock was down 5.8%

• The Smart Insulin Management Devices Market is projected to grow substantially by 2033, indicating a positive industry outlook. However, Tandem Diabetes Care's stock experienced a bearish trend.
• A reduction of 36.1% in Tandem Diabetes Care's stake by JPMorgan Chase & Co. could have contributed to the negative sentiment surrounding the stock.
• Despite beating earnings estimates, Tandem Diabetes Care remains unprofitable, leading to mixed analyst sentiment and a "Hold" consensus rating.
• The upcoming announcement of Tandem Diabetes Care's Q1 2026 results may have investors cautious, waiting for insights into the company's performance and future prospects before making investment decisions.

11.02.2026 - TNDM Stock was up 6.5%

• The bullish movement in TNDM stock today is due to the positive market reception of the company's expansion of the Mobi automated insulin delivery system to Android users. This move has significantly widened the potential user base for Tandem's technology, reflecting a strategic decision to tap into a larger market segment.
• Vanguard Group Inc.'s decision to trim its position in TNDM by 4.2% may have initially raised concerns among investors. However, the market sentiment was likely buoyed by the company's better-than-expected earnings report for the latest quarter, showcasing strong financial performance despite remaining unprofitable.
• The increased analyst attention, with Truist Securities raising its price target and Lake Street Capital Markets upgrading the stock to a Buy rating, also contributed to the positive momentum in TNDM stock, indicating growing confidence in the company's growth prospects and technological advancements in the diabetes management sector.
• Overall, Tandem Diabetes Care's strategic expansion into the Android market, coupled with favorable analyst ratings and robust financial performance, has fueled investor optimism and driven the bullish movement in the stock today.